- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00653185
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment With SYR-472 in Subjects With Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Type 2 diabetes mellitus is a complex metabolic disorder characterized by abnormal insulin secretion and glucose homeostasis, resulting from impaired pancreatic beta-cell function and insulin resistance in target tissues. The worldwide prevalence of type 2 diabetes mellitus is reaching epidemic proportions, and the total number of cases is expected to reach 221 million by 2010. The high incidence of the disease and its associated complications places a significant burden on healthcare systems.
The primary risk factor for the development of type 2 diabetes mellitus is obesity and its associated insulin resistance. Insulin resistance is characterized by an impaired response to the physiologic effects of insulin and leads to decreased cellular glucose uptake, increased hepatic gluconeogenesis, and a compensatory increase in insulin secretion that contributes to beta-cell exhaustion. Therefore in the insulin-resistant state, blood glucose and insulin levels are increased. The relationship between improved glycemic control in patients with type 2 diabetes mellitus and the delay or prevention of comorbidities has been reported in the Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study. Therefore, reduction of persistent hyperglycemia is the highest priority in treating this disease.
Diet and exercise are important and effective measures for maintaining glycemic control in individuals with insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus, particularly in the early stages of disease progression. In cases where diet and exercise alone fail to adequately maintain glycemic control, oral antidiabetic drugs are typically used. Combination oral therapy and eventually insulin are usually required to maintain lower blood glucose levels but can result in adverse effects including hypoglycemia and weight gain. Therefore, novel safe and effective antidiabetic therapies are needed.
Dipeptidyl peptidase-4 is a ubiquitous aminopeptidase that is widely expressed in many tissues; it is thought to be primarily responsible for the in vivo degradation of at least two gut-derived incretin hormones, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are both released in response to nutrient ingestion. Glucagon-like peptide-1 has been demonstrated to augment glucose-dependent insulin secretion; suppress glucagon release and hepatic gluconeogenesis; inhibit gastric emptying, and reduce appetite and food intake. Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide also have been shown to promote insulin biosynthesis and stimulate beta cell proliferation and survival. Orally available inhibitors of dipeptidyl peptidase-4 activity have been developed that increase intact postprandial glucagon-like peptide-1 levels after oral administration.
SYR-472 is a selective inhibitor of dipeptidyl peptidase-4 in development to improve glycemic control in patients with type 2 diabetes mellitus. The aim of this study is to evaluate SYR-472 in subjects with type 2 diabetes mellitus who have not previously achieved adequate glycemic control with lifestyle modification (diet/exercise) or metformin antidiabetic monotherapy. Study participation is anticipated to be up to 14 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Santiago, Chile
-
Temuco, Chile
-
-
-
-
-
Ostrava, Czech Republic
-
Prague, Czech Republic
-
-
-
-
-
Guatemala, Guatemala
-
Quetzaltenango, Guatemala
-
-
-
-
-
Eger, Hungary
-
Szentes, Hungary
-
-
-
-
-
Riga, Latvia
-
Sigulda, Latvia
-
Valmiera, Latvia
-
-
-
-
-
Kaunas, Lithuania
-
Kedainiai, Lithuania
-
Klaipeda, Lithuania
-
Vilnius, Lithuania
-
-
-
-
-
Ponce, Puerto Rico
-
-
-
-
-
Alba Iulia, Romania
-
Baia Mare, Romania
-
Bihor, Romania
-
Brasov, Romania
-
Bucharest, Romania
-
Constanta, Romania
-
Ploiesti, Romania
-
Satu Mare, Romania
-
Targoviste, Romania
-
-
-
-
-
Kemerovo, Russian Federation
-
Moscow, Russian Federation
-
St. Petersburg, Russian Federation
-
Ufa, Russian Federation
-
Volgograd, Russian Federation
-
Yaroslavl, Russian Federation
-
-
-
-
-
Banska Bystrica, Slovakia
-
Bratislava, Slovakia
-
Presov, Slovakia
-
-
-
-
-
Kharkiv, Ukraine
-
Vinnytsya, Ukraine
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
Mobile, Alabama, United States
-
Montgomery, Alabama, United States
-
Pell City, Alabama, United States
-
Tallassee, Alabama, United States
-
-
Arizona
-
Sierra Vista, Arizona, United States
-
-
California
-
Fountain Valley, California, United States
-
Los Angeles, California, United States
-
National City, California, United States
-
Pismo Beach, California, United States
-
-
Florida
-
Clearwater, Florida, United States
-
North Miami Beach, Florida, United States
-
Ocoee, Florida, United States
-
Orlando, Florida, United States
-
Plantation, Florida, United States
-
-
Georgia
-
Dawsonville, Georgia, United States
-
Gainesville, Georgia, United States
-
-
Illinois
-
Naperville, Illinois, United States
-
-
Indiana
-
Elkhart, Indiana, United States
-
Indianapolis, Indiana, United States
-
-
Louisiana
-
Slidell, Louisiana, United States
-
-
Massachusetts
-
Taunton, Massachusetts, United States
-
-
Michigan
-
Ann Arbor, Michigan, United States
-
-
Montana
-
Great Falls, Montana, United States
-
-
Nebraska
-
Scottsbluff, Nebraska, United States
-
-
Nevada
-
Las Vegas, Nevada, United States
-
-
New York
-
Brooklyn, New York, United States
-
-
North Carolina
-
Charlotte, North Carolina, United States
-
Shelby, North Carolina, United States
-
Sparta, North Carolina, United States
-
-
North Dakota
-
Fargo, North Dakota, United States
-
-
Ohio
-
Bensalem, Ohio, United States
-
Dayton, Ohio, United States
-
Kettering, Ohio, United States
-
-
Oregon
-
Central Point, Oregon, United States
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States
-
-
Rhode Island
-
Providence, Rhode Island, United States
-
-
South Carolina
-
Clemson, South Carolina, United States
-
Columbia, South Carolina, United States
-
Greer, South Carolina, United States
-
-
South Dakota
-
Rapid City, South Dakota, United States
-
-
Tennessee
-
Cleveland, Tennessee, United States
-
Kingsport, Tennessee, United States
-
-
Texas
-
Arlington, Texas, United States
-
Fort Worth, Texas, United States
-
North Richland Hills, Texas, United States
-
San Antonio, Texas, United States
-
Spring, Texas, United States
-
Sugarland, Texas, United States
-
-
Virginia
-
Hampton, Virginia, United States
-
Richmond, Virginia, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has a historical diagnosis of type 2 diabetes mellitus.
- Has undergone less than 7 days of any antidiabetic therapy except lifestyle modification (diet/exercise) within 8 weeks prior to Screening; or has received metformin monotherapy for at least 8 weeks prior to Screening and maintained a stable daily dose of metformin for at least 12 weeks prior to randomization.
- The subject receiving metformin monotherapy at randomization must have been at least 75% compliant with his or her regimen during the Run-in/Stabilization Period as determined by subject diary and investigator assessment.
- Has received no treatment with antidiabetic agents other than metformin within the 8 weeks prior to Screening.
- Has a glycosylated hemoglobin concentration between 7.0% and 10.0%, inclusive, at Screening and at the Week -1 Visit.
- The subject's fasting C-peptide concentration is greater than or equal to 0.8 ng/mL.
- Has a fasting plasma glucose concentration less than 275 mg/dL.
- If regularly uses other non-excluded medications, must be on a stable dose for at least the 4 weeks prior to Screening.
- Has a systolic blood pressure reading less than 160 mm Hg and a diastolic pressure reading less than 100 mm Hg.
- Has a hemoglobin value greater than or equal to 12 g/dL for men and greater than or equal to 10 g/dL for women.
- Has an alanine aminotransferase level is less than or equal to 3 times the upper limit of normal.
- Males have a serum creatinine value less than 1.5 mg/dL; females have a serum creatinine value less than 1.4 mg/dL.
- Has a urine albumin/creatinine ratio less than 1000 μg/mg.
- Has a thyroid-stimulating hormone level less than or equal to the upper limit of the normal range and is clinically euthyroid.
- Females must be not be pregnant or lactating, and must agree to use adequate contraception throughout the duration of the study.
- Is able and willing to monitor his or her own blood glucose concentrations with a home glucose monitor.
- Has no major illness or debility that in the investigator's opinion prohibits the subject from completing the study.
Exclusion Criteria
- Is being concurrently treated with antidiabetic therapy other than metformin and lifestyle intervention.
- Has a history of cancer, other than squamous cell or basal cell carcinoma of the skin that has not been in full remission for at least 5 years prior to Screening.
- Has a history of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.
- Has a history of treated diabetic gastric paresis.
- Has New York Heart Association class III or IV heart failure regardless of therapy.
- Has a history of coronary angioplasty, underwent coronary stent placement or coronary bypass surgery, or suffered a myocardial infarction, or stroke within the 6 months prior to Screening.
- Has a history of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.
- Has a history of infection with human immunodeficiency virus.
- Has a history of a psychiatric disorder that in the investigator's opinion will affect the subject's ability to participate in the study.
- Has ingested or received systemically injected glucocorticoids within the 3 months prior to randomization. Inhaled corticosteroids are allowed.
- Has used prescription or over-the-counter weight-loss drugs within the 3 months prior to randomization.
- Has received any investigational drug within the 30 days prior to Screening or has received an investigational antidiabetic drug within the 3 months prior to Screening.
- Has received previous treatment in an investigational study of SYR-472.
- Has a known hypersensitivity to any compound related to SYR-472.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SYR-472 25 mg QD
(with lifestyle modification and/or metformin therapy)
|
SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
|
Experimental: SYR-472 50 mg QD
(with lifestyle modification and/or metformin therapy)
|
SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
|
Experimental: SYR-472 100 mg QD
(with lifestyle modification and/or metformin therapy)
|
SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
|
Experimental: SYR-472 200 mg QD
(with lifestyle modification and/or metformin therapy)
|
SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
|
Placebo Comparator: Placebo QD
(with lifestyle modification and/or metformin therapy)
|
SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in glycosylated hemoglobin
Time Frame: Weeks 12 or Final Visit.
|
Weeks 12 or Final Visit.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in glycosylated hemoglobin
Time Frame: Weeks 4, 8, and 12 or Final Visit.
|
Weeks 4, 8, and 12 or Final Visit.
|
Change from baseline in fasting plasma glucose
Time Frame: Weeks 1, 2, 4, 8, and 12 or Final Visit.
|
Weeks 1, 2, 4, 8, and 12 or Final Visit.
|
1,5-Anhydroglucitol
Time Frame: Weeks 2, 4, 8, and 12 or Final Visit.
|
Weeks 2, 4, 8, and 12 or Final Visit.
|
Change in Proinsulin
Time Frame: Weeks 4, 8, and 12 or Final Visit.
|
Weeks 4, 8, and 12 or Final Visit.
|
Change in Proinsulin/insulin ratio
Time Frame: Weeks 4, 8, and 12 or Final Visit.
|
Weeks 4, 8, and 12 or Final Visit.
|
Change in baseline C-peptide
Time Frame: Weeks 4, 8, and 12 or Final Visit.
|
Weeks 4, 8, and 12 or Final Visit.
|
Change from baseline in insulin
Time Frame: Weeks 4, 8, and 12 or Final Visit.
|
Weeks 4, 8, and 12 or Final Visit.
|
Change in Homeostasis model assessment of beta cell function
Time Frame: Weeks 4, 8, and 12 or Final Visit.
|
Weeks 4, 8, and 12 or Final Visit.
|
Change in Homeostasis model assessment of insulin resistance
Time Frame: Weeks 4, 8, and 12 or Final Visit
|
Weeks 4, 8, and 12 or Final Visit
|
Incidence of rescue
Time Frame: Weeks 1, 2, 4, 8, and 12 or Final Visit.
|
Weeks 1, 2, 4, 8, and 12 or Final Visit.
|
Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 6.5%
Time Frame: Week 12 or Final Visit
|
Week 12 or Final Visit
|
Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 7.0%
Time Frame: Week 12 or Final Visit
|
Week 12 or Final Visit
|
Change from baseline in Fasting lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol)
Time Frame: Weeks 4, 8, and 12 or Final Visit
|
Weeks 4, 8, and 12 or Final Visit
|
Body weight
Time Frame: Weeks 4, 8, and 12 or Final Visit.
|
Weeks 4, 8, and 12 or Final Visit.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01-06-TL-SYR-472-007
- U1111-1183-0302 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on SYR-472
-
TakedaCompleted
-
TakedaCompletedDiabetes MellitusUnited States, Mexico
-
Boehringer IngelheimCompleted
-
Cairo UniversityMohamed El Sharkawy; Yomna Bayoumi; mohamed hisham gouda; Dina latifCompleted
-
TakedaTerminated